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Abstract
Background: Acute respiratory infections (ARIs) represent an important cause of morbidity and mortality in
children, remaining a major public health concern, especially affecting children under 5 years old from low-income
countries. Unfortunately, information regarding their epidemiology is still limited in Peru.
Methods: A secondary data analysis was performed from a previous cross-sectional study conducted in children
with a probable diagnosis of Pertussis from January 2010 to July 2012. All samples were analyzed via Polymerase
Chain Reaction (PCR) for the following etiologies: Influenza-A, Influenza-B, RSV-A, RSV-B, Adenovirus, Parainfluenza 1 virus,
Parainfluenza 2 virus, Parainfluenza 3 virus, Mycoplasma pneumoniae and Chlamydia pneumoniae.
Results: A total of 288 patients were included. The most common pathogen isolated was Adenovirus (49%),
followed by Bordetella pertussis (41%) from our previous investigation, the most prevelant microorganisms
were Mycoplasma pneumonia (26%) and Influenza-B (19.8%). Coinfections were reported in 58% of samples
and the most common association was found between B. pertussis and Adenovirus (12.2%).
Conclusions: There was a high prevalence of Adenovirus, Mycoplasma pneumoniae and other etiologies in
patients with a probable diagnosis of pertussis. Despite the presence of persistent cough lasting at least two
weeks and other clinical characteristics highly suspicious of pertussis, secondary etiologies should be
considered in children under 5 years-old in order to give a proper treatment.
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Background
Acute respiratory infections (ARIs) are a leading cause
of morbidity, hospitalization, and mortality among
children [1–3]. According to World Health Organization
(WHO), acute respiratory infections are responsible for
1.9 million annual deaths in children, mainly affecting
patients under 5 years old, with a higher incidence in
those from low-income countries [1, 4].
ARIs are mainly caused by a wide range of viruses and
bacteria [5, 6]. Viruses are isolated in up to 80% of cases,
the most common pathogens are the respiratory syncytial
virus (RSV) A and B, influenza (Flu) A, B and C, para-
influenza (PIV) types 1, 2, 3 and 4, coronavirus and rhino-
virus [7, 8]. Classically, S. pneumoniae and H. influenzae
type b are the most commonly isolated bacteria in both
throat and nasopharyngeal specimens from patients with
ARIs [9, 10]. However, in resource-limited countries, atyp-
ical bacteria such as Mycoplasma pneumoniae, Chlamydia
pneumoniae, and Bordetella pertussis can play an import-
ant role in ARIs and can be detected in more than 40% of
patients [2, 11–14].
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Although numerous pathogens are associated with
ARIs, their clinical manifestations are very similar,
regardless of the causative agent. Thus, laboratory iden-
tification of the etiological agent is key in order to give a
proper treatment and avoid the overuse of antibiotics
[15]. Moreover, ARIs due to atypical bacterial infections
have become a global concern especially after their
reemergence in low-income countries [11, 16].
Simultaneous infections with virus and bacteria species
have become an obstacle for clinicians, their prevalence
has significantly increased, with studies discovering
co-infections in more than 45% of cases [11, 17–19].
Additionally, these coinfections have been associated with
longer hospitalization periods, worse clinical outcomes
and increased mortality, again highlighting the importance
of molecular etiological confirmation [17, 19, 20].
Bordetella pertussis represents a persistent cause of
morbidity and mortality in children [21]. Accounting for
an estimated 16 million cases and 195,000 deaths world-
wide [22]. In a previous study we conducted on children
under 1-year-old with a probable diagnosis of Pertussis
from 5 Peruvian hospitals, we reported a prevalence of
39.54% pertussis cases [14]. With more than 60% of
cases without an identified pathogen, hence a more
comprehensive etiological analysis was required.
The main objective of this study was to detect the
presence of 8 respiratory viruses (Influenza-A,
Influenza-B, RSV-A, RSV-B, Adenovirus, Parainfluenza-1,
Parainfluenza-2 and Parainfluenza-3) and atypical bac-
teria (Mycoplasma pneumoniae, Chlamydia pneumonia),
via Polymerase Chain Reaction in samples from Peruvian
children under 5 years-old previously analyzed for B.
Pertussis.
Methods
Patients and study design
A secondary data analysis was performed from a previ-
ous cross-sectional study conducted from January 2010
to July 2012 in 5 Peruvian hospitals: Instituto Nacional
de Salud Del Niño, Hospital Edgardo Rebagliati Martin,
Hospital de Emergencias Pediátricas, Hospital Nacional
Cayetano Heredia and Hospital Regional de Cajamarca.
The original study enrolled children under 5 years old
admitted to the pediatric wards as probable Pertussis
cases. However, in this original study, only patients
under 1-year-old were included in the final analysis. A
probable case was defined if patients presented parox-
ysms of coughing, or inspiratory “whoop” or post-tussive
vomiting in the setting of an acute cough illness of any
duration in the absence of another more likely diagnosis.
In patients under 1 year-old apnea (with or without
cyanosis) was also considered. All patients with chronic
pulmonary conditions, cardiac disease or immunodefi-
ciency were excluded. Patient who received antibiotics 7
days prior to the enrollement were also excluded.
(Fig. 1).
This study included a total of 288 children under 5
years old hospitalized with a probable diagnosis of
Pertussis, requiring further comprehensive etiological
identification. All samples were analyzed via PCR for the
following etiologies: Influenza-A, Influenza-B, RSV-A,
RSV-B, Adenovirus, Parainfluenza 1 virus, Parainfluenza
2 virus, Parainfluenza 3 virus, Mycoplasma pneumoniae
and Chlamydia pneumoniae.
Ethics statement
This study has been approved by Ethics Committees of
the Universidad Peruana de Ciencias Aplicadas. Parents
and caregivers signed a written consent in the previous
study which included a section that granted the investi-
gators permission for a possible future use of the sam-
ples that could be given as an extension of the original
research.
Samples
Nasopharyngeal samples were obtained by inserting a
swab into both nostrils parallel to the palate (Mini-Tip
Culture Direct, Becton-Dickinson Microbiology System,
MD 21152, USA) and a second swab from the posterior
pharyngeal and tonsillar areas (Viral Culturette,
Becton-Dickinson Microbiology Systems, MD, USA).
Both nasal and pharyngeal swabs were placed into the
same tube containing viral transport medium (minimal
essential medium with 2% fetal bovine serum, amphoter-
icin B 20 μg/ml, neomycin 40 μg/ml). Two aliquots of
each fresh specimen were stored at − 20 °C to be used
for posterior analysis of respiratory viruses and detect
atypical pathogens by PCR.
RNA/DNA extraction
RNA/DNA extraction was performed from 200 μL of the
serum samples with the High Pure RNA Isolation Kit
(Roche Applied Science, Mannheim, Germany), in
accordance to the manufacturer’s instructions. Viral
RNA/DNA obtained after extraction was eluted in
100 μl of nuclease-free water and then processed or
stored at − 20 °C until use.
Reverse transcription polymerase chain reaction (RT-PCR)
for the analysis of respiratory viruses
RT-PCR for Influenza-A, Influenza-B, RSV-A, RSV-B
and Adenovirus virus were performed using a BHQ
quencher probe at 125 nM and 250 nM of primers in a
final volume of 20 μl. Five microliters of the extracted
RNA was combined with 15 μl of the master mix.
RT-PCR conditions was 60 cycles of 15 s at 95 °C and 45 s
at 60 °C. This process was performed in Light Cycler® 2.0
Instrument and the data was analyzed with the LightCycler®
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Software 4.1 (Roche Diagnostic, Deutschland-Mannheim,
Germany). The primers and the probe for Influenza A and
B were described by Selvaraju et al., 2010 [23], for
RSV-A and RSV-B were described by Liu W. et al.,
2016 [24] and for Adenovirus was described by Heim
et al., 2003 [25].
For he case of Parainfluenza 1 virus, Parainfluenza 2
virus and Parainfluenza 3, the primers and conditions
for RT-PCR were described by Coiras et al., 004 [26].
Polymerase chain reaction (PCR) for the analysis of
atypical pathogens Mycoplasma pneumoniae, Chlamydia
pneumoniae and Bordetella pertussis
Polymerase chain reaction was performed with 5 μL of
template DNA, polymerase (GoTaq; Promega, Madison,
Wisconsin, USA). The Primers and conditios used for
Mycoplasma pneumoniae, Chlamydia pneumoniae were
descrited by del Valle et al.; 2017 [11] and primers and
conditions used for Bordetella pertussis were describe by
Castillo et al., 2015 [14]. Amplified products were
recovered from the gel, purified (SpinPrep Gel DNA Kit;
San Diego, CA) and sent for commercial sequencing
(Macrogen, Korea).
Statistical analysis
A database was generated in Microsoft Excel® 2015
(Microsoft Corporation, California, USA), all data was
then exported to STATA® v13.0 (StataCorp, College
Station, Texas, USA). Quantitative variables were de-
scribed as frequencies and percentages for each group.
The association was established by the Pearson correl-
ation analysis (r) and the results presented in a scatter
matrix with the ellipse plotted at 95% confidence.
Results
A total of 288 patients under 5 years old with a probable
diagnosis of B. ertussis were studied thouroughly for
specific etiological identification. More than 80% of our
study population were infants between 1 to 5 months
old with a slightly higher number of males (56.3%). The
group of infants between 29 days – 2 months-old
(27.4%) and the group between 3 and 5months-old
(27.4%) were the most predominant, closely followed by
the group between 2 and 3months-old (26.4%)
(Additional file 1: Table S1).
From our previous study, 118 cases of Bordetella
pertussis were confirmed via PCR, leaving potentially
59% of samples without etiological identification. Thus,
all 288 were analyzed for the presence of Influenza-A
(Flu-A), Influenza-B (Flu-B), RSV-A, RSV-B, Adenovirus
(ADV), Parainfluenza 1 virus (PIV-1), Parainfluenza 2
virus (PIV-2), Parainfluenza 3 virus (PIV-3), Mycoplasma
pneumoniae and Chlamydia pneumoniae. The most
common pathogen isolated was Adenovirus at 49% (141/
288), followed by Bordetella pertussis at 41% (118/288),
Mycoplasma pneumonia at 26% (75/288) and Flu-B at
19.8% (57/288) (Additional file 1: Table S1-A). The iden-
tification of these infectious agents has made it possible
to establish remarkably that coinfections were present at
58% (167/288) of patients. Thus, cases of infection due
Fig. 1 Flow chart with all patients enrolled in the study
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to a single infectious agent were 28.8% (80/288), and
where the presence of ADV was 10.2% (25/80) and for
B. pertussis was 9.8% (24/80), followed by M. pneumo-
niae with 6.1% (15/80). Furthermore, the prevalence of
these infectious agents were accumulated in children
under 5 months of age (Additional file 1: Table S1-B).
As indicated above, in infected children (247 cases)
coinfections stand out considerably (Additional file 2:
Table S2). The coinfections found involve 2 to 6 differ-
ent infectious agents, being the most frequent the coin-
fections of 2 agents with 39.6% (97/247) and those
involving 3 agents with frequency of 23.2% (57/247).
The most frequent association was the bacterial-viral co-
infection, and the combination between Bordetella-ADV
and Mycoplasma-ADV were the most common involve-
ment reported with 12.2% (30/247) y 6.5% (16/247),
respectively. However, the Bordetella-Mycoplasma asso-
ciation was very reduced (Additional file 2: Table S2), In
addition, it is interesting to note that the associations in
coinfections increase the frequency of infectious agents
such as Chlamydia, Flu-B and RSV-A as observed in
Additional file 1: Table S1 (compare 1A with 1B).
Regarding vaccination status, 65.25% (77/118) of the
positive cases were unvaccinated. However, the majority
of these children (40/77) were under two months of age.
An unknown vaccinated status was observed in 5.93%
(7/118) of patients positive for B. pertussis. A marked
decrease was observed in children who had received at
least one dose of vaccination, with a prevalence of
18.64% (22/118) (Additional file 3: Table S3).
In our population, the most common clinical symp-
toms registered at admission were vomiting (47.2%),
whooping (46.5%) and shortness of breath (43.1%),
followed by fever (35.4%) and cyanosis (28.8%). A wide
spread distribution of symptoms distribution was ob-
served when patients symptoms were individually assessed
based on etiological group. Only 6 pathogens had symp-
toms that were present in more than 50% of each group.
For example, vomiting was more commonly reported
among children with Flu-A, RSV-A, Parainfluenza-1 and
B. pertussis (Additional file 4: Table S4-A). However, the
difficulty in establishing clear clinical symptoms associated
with infectious causal agents is due to the high frequency
of coinfections. Therefore, Additional file 4: Table S4-B
has recorded the clinical symptoms of cases of
infection with a single agent, and the association of
these clinical symptoms are shown in Fig. 2. Thus, a
clear non-association can be observed between
Mycoplasma and Flu-B, ADV or Bordetella; the same
happens for Flu-B and Bordetella or ADV. This
non-association means that the only infectious agent
could be identified taking into account the clinical
symptoms of the children as shown in Additional file
4: Table S4-B.
The most common complications were acute bron-
chial obstructive syndrome (ABOS) and pneumonia in
56.6 and 28.1% of our population respectively. ABOS
was the most frequent complications among patients
with positive samples for RSV-A, Flu-A, ADV, M. pneu-
moniae,C. pneumoniae and B. pertussis. (Additional file 5:
Table S5-A). However, when the complications of chil-
dren affected by a single infectious agent are analyzed, it
is clearly demonstrated that ABOS is also a complication
of Flu-B. In addition, it is noteworthy that ABOS occurs
in 61% (25/41) of the negative cases (Additional file 5:
Table S5-B).
Finally, a seasonal distribution was described for each
specific microorganism. Positive samples for ADV and
Mycoplasma pneumoniae were observed across the
whole study period. On the contrary, most of the B.
pertussis cases were detected from May 2011 to March
2012. RSV-A and Chlamydia were mostly detected from
March to May 2010; however, the same distribution was
not observed in the following year (Fig. 3).
Discussion
ARIs as the most common cause of morbidity and mor-
tality in children, remaining a major concern, especially
affecting children under 5 years old from low-income
countries [1–4]. Unfortunately, information regarding
their epidemiology is still limited in Peru [7, 11].
In recent years, there has been evidence of pertussis
resurgence in Latin America, despite the introduction of
the vaccine [14, 27, 28]. This bacterium is highly
contagious and virulent, about half of the infected
children under one year of whooping cough require
hospitalization. In Peru, the national immunization
program administers the combined pentavalent vaccine
(DPT, HvB, Hib) at 2, 4, 6 months with reinforcements
at 18 months and 4 years [29, 30]. Thus, we conducted a
previous study on Peruvian children with a probable
diagnosis of Pertussis and reported a Bordetella pertussis
prevalence of 39.5% [14]. However, the classical presen-
tation of pertussis has proven to be not enough to
achieve a definitive diagnosis and laboratory tests are of
the utmost importance for etiological confirmation to
avoid overdiagnosis [28, 31, 32]. In the light of possible
coinfections and more than 60% of patients without an
etiological identification in our previous study, we con-
ducted a new comprehensive analysis to detect viral and
atypical bacterial etiologies in all our patients.
From a total of 288 samples analyzed from children
under 5 years old with a probable diagnosis of Pertussis,
the most common pathogen isolated was ADV in 49% of
samples, followed by B. pertussis in 41% from our
previous analysis. Although this study was conducted in
patients with ARI with a highly suspicious pertussis
diagnosis, other studies on children with ARI have
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identified ADV as one of the most prevalent etiologies
[2] Although, the viral and bacterial prevalence may
vary widely depending on the population characteris-
tics [8, 33, 34].
Interestingly, our population were children with a
highly suspicious clinical diagnosis of pertussis and
despite that whooping was present in 46.5% of patients,
ADV was the most common etiology isolated. Further-
more, a great number of patients with ADV infection
presented with clinical symptoms very common among
patients with pertussis such as whooping (51.1%), short-
ness of breath (43.4%) and vomiting (47.5%). Similarly, a
recent study has reported that gastrointestinal symptoms
and difficulty breathing are among the most common
type of presentations in children [35]. Additionally, ADV
has been historically identified as a major cause of
pertussis-like syndrome, which results in the likelihood
of a pertussis misdiagnosis in the absence of laboratory
Fig. 3 Viral and bacterial etiologies seasonal distribution
Fig. 2 Association of the clinical symptoms in hospitalized children with a diagnostic for a single infectious agent. The graph is symmetrical on
the diagonal. The squares in blue show the non-association
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confirmation [36–38]. In this way, we have shown that
patients with infection by ADV and B.pertussis as a
single infectious agent have similar symptoms (Fig. 1).
It is also important to highlight the presence of Myco-
plasma pneumoniae (26%) and Chlamydia pneumoniae
(17.7%) among our patients. In a previous study, in chil-
dren with ARIs, we reported a very similar prevalence of
Mycoplasma pneumoniae and Chlamydia pneumoniae
in 25.2 and 10.5%, respectively [11]. Demonstrating the
high prevalence of these atypical bacteria among Peru-
vian children with ARIs. Our results from this current
study also make noteworthy that clinical manifestations
by Mycoplasma pneumoniae and Flu-B, ADV, or B.
pertussis are distinguishable when the infection is due to
infectious agent alone. However, in coinfections the
symptoms were undestinguibles (see Table S4).
Additionally, in our previous study coinfections between
these bacteria and viruses were also frequent; present in
67.4% of samples, coinfections between were the most
common combination and the association between Myco-
plasma pneumoniae with VRS-A was the most frequent
one observed in 9.59% of patients [11]. Surprisingly, in this
study, we have observed 58% of coinfections in our
samples, again being the viral-bacterial association the
most frequent and the most commonly detected coinfec-
tion involving Bordetella pertussis-ADV and Mycoplasma
pneumoniae-ADV with frequencies of 12.2 and 6.5%, re-
spectively. Another study in children, although in patients
with community-acquired Pneumonia, also have reported
coinfections in M. pneumoniae as the most common bac-
teria detected in association with a virus [39]. Thus, to
avoid under-diagnosis, pertussis should be considered in
patients with cough, especially if chronic, even when M.
pneumoniae have been documented [40].
Another common coinfection was B. pertussis and
Flu-B present in 9 patients. Although viral-bacterial
coinfections are commonly associated with worse
clinical courses and longer hospitalizations [17, 19, 20].
Recent investigations have reported similar clinical
outcomes in infants hospitalized with B. pertussis and
another respiratory virus coinfection [20]. However,
noteworthy attention should be given to the B. pertussis
and ADV coinfection in infants. A study compared in-
fants with RSV and RSV-B. pertussis coinfection report-
ing similar disease severity; however, patients with this
coinfection clearly needed more respiratory care and nu-
tritional support [18]. Consequently, our only patient
with RSV-A and pertussis presented with cyanosis and
required advance respiratory support.
The variations in the rate and pattern of coinfection in
patients with ARIs may be related to seasonal and
geographical factors [39]. In our study, we intended to de-
scribe all detected pathogens and their seasonal distribu-
tion. Even though we were not able to describe any clear
pattern, it is worth mentioning the high prevalence of
ADV and M. pneumoniae across all of the study period, as
well as the increasing prevalence of B. Pertussis on 2012.
Limitations
Our study had some limitations. As mentioned in our
previous study, due to our study design we were not able
to establish causality between the pathogens isolated in
our samples and our patient’s clinical presentation.
Additionally, missing samples, we were not able to
perform an etiological analysis in 104 samples from our
previous study. We were not able to perform an etio-
logical analysis in 104 samples from our previous study.
Aditionally, there is still controversy if PCR alone can be
used as a confirmatory method for M. pneumoniae
diagnosis [41, 42]. Commercial PCR tests have high spe-
cificity and are currently a method of choice for direct
pathogen detection [41, 43]. However, studies recom-
mend that PCR alone should not replace serology and
the combination of both could be good screening tests
for reliable and accurate diagnosis of M. pneumoniae
[41]. Moreover, other more recent studies suggest that a
positive PCR or serology for M. pneumoniae may be un-
able to differentiate between asymptomatic carriage and
symptomatic infection [44].
To date, the available published information regarding
the etiological prevalence of ARIs in Peruvian children is
still limited. Despite the high incidence of Pertussis,
especially in vulnerable populations such as infants, to
date to establish a etiological diagnosis in low income
countries is still challenging [11, 16, 43]. Moreover, the
relationship between the clinical severity and coinfec-
tions in respiratory pathogens remains inconclusive. Our
study is among the first ones to describe multiple viral
and bacterial etiologies in patients with a high clinical
suspicion of pertussis [45, 46]. Further investigations
should be conducted in order to understand the role of
these pathogens in Peruvian children.
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